Data presented by Biogen and Swedish Orphan Biovitrum supported Alprolix’ safety, efficacy and pharmacokinetic profile. According to the new data, one injection of Alprolix helped control more than 90 ...
Please provide your email address to receive an email when new articles are posted on . Recombinant Factor IX Fc fusion protein appeared safe and effective in the prevention and treatment of bleeding ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved the first long-acting recombinant coagulation factor IX concentrate for children and ...
Alprolix is a recombinant clotting factor therapy developed using Fc fusion technology to prolong circulation in the body. The Food and Drug Administration (FDA) has approved updated labeling Alprolix ...
Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (SOBI.ST) and collaboration partner Biogen have received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European ...
STOCKHOLM, July 13, 2020 /PRNewswire/ -- Final results from the PUPs A-LONG and PUPs B-LONG studies assessing the efficacy and safety of Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) ...
Biogen Idec ( BIIB) announced that its hemophilia B drug, Alprolix, gained approval in Canada. Health Canada approved the drug for controlling and preventing bleeding as well as for routine ...
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix (rFIXFc ...
(Reuters) – Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. Hemophilia B is a rare, inherited disorder ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec’s (NASDAQ: BIIB) new hemophilia drugs, ELOCTATE (rFVIIIFc) and ALPROLIX (rFIXFc), are poised to capture a significant share of the hemophilia market and ...
The U.S. Food and Drug Administration has approved Alprolix, Coagulation Factor IX, Fc Fusion Protein as a treatment option for patients with Hemophilia B. Alprolix, manufactured by Cambridge, ...
Biogen Idec ( BIIB) and Swedish Orphan Biovitrum AB recently presented new data on their hemophilia B candidate, Alprolix, at the XXIV International Society on Thrombosis and Haemostasis (ISTH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback